Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of Campinas, Brazil
This crossover, double-blind study will include 12 resistant hypertensive subjects - regularly followed at the Outpatient Resistant Hypertension Clinic/UNICAMP - which will randomized assigned to (1) saline infusion followed by infliximab infusion (TNF-α inhibitor, 3 mg/kg) and (2) infliximab followed by saline, for two hours and washout of the 40-day period between both infusions. It is expected that the TNF-α inhibition regulates hemodynamic parameters, such as mean BP, cardiac Output, total peripheral resistance, which may allow a better rational approach for the RH treatment.
Age
35–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
the diagnosis recommended by the AHA Statment on Resistant Hypertension (2008)
a 6-month period clinic follow-up
give written informed consent form
You may not be if
secondary Hypertension
pseudoresistance hypertension (poor medication adherence and white coat hypertension)
patients with symptomatic ischemic heart disease, impaired renal function, liver disease and history of stroke, myocardial infarction and peripheral vascular diseases